Search

Primary localized cutaneous nodular amyloidosis (PLCNA) is included in the primary forms of cutaneous amyloidosis along with macular and lichenoid amyloidosis. It is a rare disease attributed to plasma cell proliferation and deposition of immunoglobulin light chains in the skin. We present the case of a 75-year-old woman with a personal history of Sjogren's syndrome (SjS), who consulted for asymptomatic yellowish, waxy nodules on the left leg. Dermoscopy of the lesions showed a smooth, structureless, yellowish surface with hemorrhagic areas and few telangiectatic vessels. Histopathology revealed an atrophic epidermis and deposits of amorphous eosinophilic material in the dermis with a positive Congo red stain. The diagnosis of nodular amyloidosis was made. Periodic reevaluation was indicated after the exclusion of systemic amyloidosis. PLCNA is often associated with autoimmune connective tissue diseases, and up to 25% of all PLCNA cases occur in patients with SjS. Therefore, in addition to ruling out systemic amyloidosis, screening for possible underlying SjS should be performed when the diagnosis of PLCNA is confirmed. [ABSTRACT FROM AUTHOR]

Primary localized cutaneous nodular amyloidosis (PLCNA) is a rare condition attributed to plasma cell proliferation and the deposition of immunoglobulin light chains in the skin without association with systemic amyloidosis or hematological dyscrasias. It is not uncommon for patients diagnosed with PLCNA to also suffer from other auto-immune connective tissue diseases, with Sjögren's syndrome (SjS) showing the strongest association. This article provides a literature review and descriptive analysis to better understand the unique relationship between these two entities. To date, 34 patients with PLCNA and SjS have been reported in a total of 26 articles. The co-existence of PLCNA and SjS has been reported, especially in female patients in their seventh decade of life with nodular lesions on the trunk and/or lower extremities. Acral and facial localization, which is a typical localization of PLCNA in the absence of SjS, seems to be much more unusual in patients with associated SjS. [ABSTRACT FROM AUTHOR]

Background: UVA1 phototherapy is a treatment used for multiple dermatological conditions. The optimal therapeutic regimens and dosing of UVA1 are a matter of debate. The dosages used vary widely between published studies and there are no evidence-based protocols that provide data on dosage, duration, or the role of maintenance therapy. The purpose of this study is to evaluate the experience in our medical center regarding treatment with UVA1, as well as the degree of patient satisfaction with the treatment according to their pathology. Methods: We present a retrospective evaluation of outcomes, treatment tolerability, and satisfaction in adult patients using a low dose of UVA1 phototherapy, administered in our dermatologic service between 2019 and 2022. Results: A total of 78 patients were treated with UVA1, of whom 46 patients (59%) were over 18 years old, completed treatment, and gave their consent. The overall objective clinical response rate was 91.30% (42/46), achieving a complete response in 17 (36.96%) patients, partial response in 25 (54.34%), and no response in 4 (8.70%). The complete response rates recorded were high in morphea, scleredema, or chronic hand eczema. In terms of the level of satisfaction objectively measured by TSQM-9 version 1.4, highlighting high scores obtained in mastocytosis, systemic sclerosis, morphea, scleredema, chronic hand eczema, or prurigo nodularis (over 65 points). Conclusions: We present a review of treatment with UVA1 phototherapy at low doses with good response in a wide variety of dermatological pathologies. [ABSTRACT FROM AUTHOR]

Of these, four patients (10%) suffered primary failure by not reaching PASI75 at week 16, and six patients (15%) suffered secondary failure by losing PASI75 at week 16. For patients initiating I de novo i biologic therapy, the inclusion criteria were patients over 18 years of age, with moderate-to-severe psoriasis who had a Psoriasis Area and Severity Index (PASI) and BSA (body surface area) greater than 7, and/or Dermatology Life Quality Index (DLQI) higher than 10. Specifically, 73 patients with stabilized disease started treatment with biosimilar adalimumab after switching from the original adalimumab, and 40 patients started I de novo i biosimilar adalimumab. [Extracted from the article]

Contact urticaria syndrome caused by alpha-lipoic acid in a master formula for vulvar lichen sclerosus Keywords: 1,2-dithiolane-3-pentanoic acid; CAS 1077-28-7; case report; contact urticaria syndrome; immediate-type reaction; thioctic acid; vulvar lichen sclerosus; -lipoic acid EN 1,2-dithiolane-3-pentanoic acid CAS 1077-28-7 case report contact urticaria syndrome immediate-type reaction thioctic acid vulvar lichen sclerosus -lipoic acid 136 137 2 07/11/23 20230801 NES 230801 Genital areas are highly susceptible to irritants and allergens and, therefore, to the development of contact dermatitis. 1,2-dithiolane-3-pentanoic acid, CAS 1077-28-7, case report, contact urticaria syndrome, immediate-type reaction, thioctic acid, vulvar lichen sclerosus, -lipoic acid. [Extracted from the article]

The history of radiation exposure, clinical presentation and histology confirmed the diagnosis of radiation dermatitis. Radiation dermatitis is classified as either acute (in the first 90 days after radiation) or chronic (months to years after radiation). [Extracted from the article]

This article presents a case study on a 14-year-old male goalkeeper who developed hand eczema from wearing goalkeeper gloves. The patient experienced recurrent and pruritic lesions on his hands, which improved with the use of a cream. Patch testing revealed positive reactions to 2-mercaptobenzothiazole and epoxy resin, both of which are commonly found in sports equipment. The patient was diagnosed with allergic contact dermatitis caused by the goalkeeper gloves and was advised to wear cotton gloves as a first layer. After three months of treatment, the patient showed significant improvement. The article emphasizes the importance of investigating patients with patch testing, including sports equipment, and highlights the need for collaboration with manufacturers to identify allergens. [Extracted from the article]

Punch grafting is a technique that can improve and accelerate the healing of hard-to-heal wounds and reduce the associated pain. It is a simple and inexpensive procedure that can be performed in the examination room. It is a technique that uses small split-thickness skin grafts (STSG) to promote the growth of epithelial tissue. It has been described as being used mainly to treat ulcers of venous, arterial, hypertensive and diabetic aetiology. Punch grafting has also been used successfully in postoperative dermatological surgical wounds. This article describes and details the performance of the punch-graft technique, with special emphasis on aftercare and the role of nurses in the procedure. A clinical case is presented of a patient who underwent surgery for cutaneous squamous cell carcinoma and whose primary closure was rejected. It was decided to place the STSGs obtained from the anterior aspect of the patient's thigh after preparation of the recipient area to ensure an optimal wound bed. The patient's pain subsided within a few days, and the wound healed within weeks with weekly dressing changes. [ABSTRACT FROM AUTHOR]

Keywords: case report; lettuce; occupational dermatoses; patch test; prick-to-prick test; protein contact dermatitis EN case report lettuce occupational dermatoses patch test prick-to-prick test protein contact dermatitis e175 e177 3 05/12/23 20230501 NES 230501 I Lactuca sativa i L. (genus Lactuca) belongs to the plant family I Asteracea i (Compositae). The patient was diagnosed with lettuce protein contact dermatitis (based on immediate allergy to lettuce, which was confirmed by SPT positivity), and overlap allergic contact dermatitis to parthenolide. [Extracted from the article]